Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbott's Humira Gains JIA Approval | Contract Pharma

What are you searching for?

Sign in

Abbott’s Humira Gains JIA Approval

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott received FDA approval to market Humira as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older. The approval is based on safety and efficacy results from a study of JIA patients four to 17 years old. Humira is the first biologic treatment to receive FDA approval for this condition since 1999.
   
JIA is the most common chronic rheumatic disease in children with onset before age 16. Typical symptoms include stiffness when awakening, limping, and joint swelling, which may limit the mobility of the affected joints. JIA is the sixth approved indication for Humira since 2002.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters